What's new

Orphan designation: hydroxocobalamin acetate Treatment of homocystinuria and/or methylmalonic acidaemia due to genetic defects of intracellular cobalamin processing, 26/02/2025 Positive

Orphan designation: hydroxocobalamin acetate Treatment of homocystinuria and/or methylmalonic acidaemia due to genetic defects of intracellular cobalamin processing, 26/02/2025 Positive

Mar 11, 2025 - 13:27
 0
Orphan designation: hydroxocobalamin acetate Treatment of homocystinuria and/or methylmalonic acidaemia due to genetic defects of intracellular cobalamin processing, 26/02/2025 Positive
Orphan designation: hydroxocobalamin acetate Treatment of homocystinuria and/or methylmalonic acidaemia due to genetic defects of intracellular cobalamin processing, 26/02/2025 Positive
Read More

Tags:

Previous Article

EVgo opens first fast charging stations deployed through Toyota’s “Empact” vision

Next Article

SEIA and Wood Mackenzie: US adds 50GW of new solar capacity in 2024

Related Posts

European Medicines Agency post-authorisation procedural...

Feb 18, 2025  0

Minutes of the COMP meeting 3-5 December 2024

Feb 11, 2025  0

Human medicines European public assessment report (EPAR): Eurneffy, epinephrine, Date of authorisation: 22/08/2024, Revision: 3, Status: Authorised

Human medicines European public assessment report (EPAR...

Feb 9, 2025  0